Clearstead Trust LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Clearstead Trust LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 345.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,827 shares of the medical research company's stock after purchasing an additional 1,417 shares during the period. Clearstead Trust LLC's holdings in Thermo Fisher Scientific were worth $970,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Sugarloaf Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 6.9% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company's stock valued at $156,000 after buying an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton lifted its holdings in Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company's stock worth $279,000 after purchasing an additional 19 shares during the last quarter. Tsfg LLC boosted its position in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company's stock worth $132,000 after purchasing an additional 19 shares during the period. Pacifica Partners Inc. raised its position in shares of Thermo Fisher Scientific by 16.5% in the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company's stock valued at $69,000 after purchasing an additional 20 shares during the period. Finally, Retirement Planning Group LLC lifted its stake in shares of Thermo Fisher Scientific by 4.9% in the fourth quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company's stock worth $237,000 after buying an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company's stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,277 shares of company stock worth $35,373,364. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TMO. Barclays boosted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday, April 25th. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 price target for the company. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $607.35.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $1.13 during mid-day trading on Friday, reaching $572.38. The company had a trading volume of 1,749,670 shares, compared to its average volume of 1,409,187. The company's 50-day moving average is $575.39 and its 200-day moving average is $532.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company has a market capitalization of $218.48 billion, a P/E ratio of 36.71, a P/E/G ratio of 2.37 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analysts' expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.